CompletedNCT00307619
Topiramate or placebo added to therapy for binge eating
About this title
An Efficacy and Tolerability Study for Topiramate in Obese Patients With Binge Eating Disorder.
Read the official source — NCT00307619Medication studyAges 18–60Eating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 73
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00307619
- Official title
Show the full official title
Randomized, Double-blind Placebo Controlled Trial With Topiramate for the Treatment of Obese Patients With Binge Eating Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag Farmaceutica Ltda.
Did this study involve medication?
Yes. The study involved medication, including topiramate.
Who was this study for?
Listed age limits: 18 years to 60 years.
